Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company which focuses on the development of drugs for the treatment of light related severe skin disorders. The company’s lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP) and is approved in Europe, Australia and the US for treating adult EPP patients. Its other products under development includes CUV9900 and VLRX001 among others. Clinuvel Pharmaceuticals also focused on developing a pediatric formulation of Scenesse for EPP and OTC products for general photoprotective application. The company through its subsidiaries has operations in Australia, Switzerland, Ireland, the UK, the US and Singapore. Clinuvel Pharmaceuticals is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
L 11 535 Bourke St, Melbourne, Victoria, 3000
Website
www.clinuvel.com
Telephone
61 3 96604900
No of Employees
16
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CUV (ASX)
Revenue (2021)
$33.3M
45.9%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
64.3%
(2021 vs 2020)
Market Cap*
$535.6M
Net Profit Margin (2021)
XXX
12.7%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Commercial: | Scenesse |
| Scenesse (Afamelanotide) | Prenumbra |
| Pipeline products: | |
| XXX | |
| XXX | |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Others | In February, the company announced the first disease-free subjects have received afamelanotide as part of the CUV151 mechanistic study to evaluate the impact of the drug on DNA damaged skin. |
| 2021 | Contracts/Agreements | In November, the company entered into a longer term commercial agreement with one of its strategic partners for the scaled supply of adrenocorticotropic hormone (ACTH) drug substance to current Good Manufacturing Practices (cGMP) standard. |
| 2021 | Corporate Changes/Expansions | In November, the company expanded its pharmaceutical development portfolio with NEURACTHEL, novel formulations of the melanocortin adrenocorticotropic hormone. |
Competitor Comparison
| Key Parameters | Clinuvel Pharmaceuticals Ltd | MEI Pharma Inc | Rhinomed Ltd | Opthea Ltd | biosensis Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | United States of America | Australia | Australia | Australia |
| City | Melbourne | San Diego | Richmond | Melbourne | Thebarton |
| State/Province | Victoria | California | Victoria | Victoria | South Australia |
| No. of Employees | 16 | 76 | - | 5 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Phillipe J. Wolgen, Ph.D. | Managing Director; Director; Chief Executive Officer | Executive Board | 2005 | - |
| Darren M. Keamy | Secretary; Chief Financial Officer | Senior Management | 2006 | - |
| Dennis Wright, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Willem Blijdorp | Chairman | Non Executive Board | 2019 | - |
| Lachlan Hay | Director - Global Operations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer